Our Oral GLP-1 Drops offer a convenient, needle-free alternative for GLP-1 weight loss support
Wang W, Nevrez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J
TRIUMPH-1's 11.3% represents an improvement over TRIUMPH-4's 18.2%, and suggests the general obesity population tolerates retatrutide better than the older, more comorbid OA population in TRIUMPH-4
For very long peptides or molecules with favorable conjugation sites, fragment approaches may still offer advantages
Hormonal and Metabolic Adjustment GLP-1 medications are not just appetite suppressants
Retatrutide exhibits highest potency at the GIP receptor (8.9-fold greater than endogenous GIP), with moderate activation of the GLP-1 receptor (0.4-fold) and lower, yet functional, glucagon receptor activity (0.3-fold)